A Study of Golimumab (CNTO148) Monotherapy in Patients With Active Rheumatoid Arthritis.

Trial Profile

A Study of Golimumab (CNTO148) Monotherapy in Patients With Active Rheumatoid Arthritis.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 05 Nov 2015

At a glance

  • Drugs Golimumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms GO-MONO
  • Most Recent Events

    • 14 Nov 2012 Long-term efficacy and tolerability results at 104 weeks presented at the 76th Annual Scientific Meeting of the American College of Rheumatology and the 47th Annual Meeting of the Association of Rheumatology and Health Professionals.
    • 09 Nov 2012 Primary endpoint 'American-College-of-Rheumatology-20%-response-criteria' has been met.
    • 14 Sep 2012 Results published in the Annals of the Rheumatic Diseases.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top